The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.

The updated 2024 NCCN...

11/15/2024

Journal of Clinical Pathways

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Recent Stories

Interview

Integrating Real-World Evidence and Clinical Trial Data in CLL Management

01/17/2025

Matthew S. Davids , MD, MMSc;

In this interview, Matthew S. Davids, MD, MMSc, discusses the role of real-world evidence in chronic lymphocytic leukemia (CLL) management, treatment considerations for high-risk and comorbid patients, strategies for therapy discontinuation,...

In this interview, Matthew S....

01/17/2025

Journal of Clinical Pathways

Interview

Personalizing Radiotherapy for Endometrial Cancer: Balancing Innovation and Quality of Life

01/17/2025

Kara D. Romano , MD;

In this interview, Kara D. Romano, MD, University of Virginia, discusses advancements in radiation therapy for endometrial cancer, the integration of systemic therapies, the impact of treatment on quality of life, and the role of clinical...

In this interview, Kara D....

01/17/2025

Journal of Clinical Pathways

Interview

Advancing Biomarker Validation and Emerging Treatments in Metastatic Breast Cancer

01/16/2025

Cynthia X. Ma , MD, PhD;

In this interview, Cynthia X. Ma, MD, PhD, Washington University School of Medicine, discusses challenges in biomarker validation, the role of combination therapies, promising novel agents, and the integration of emerging treatments for...

In this interview, Cynthia X....

01/16/2025

Journal of Clinical Pathways

News

Racial Disparities in Immune Checkpoint Inhibitor Treatment and Survival Among Patients With NSCLC

01/15/2025

Hannah Musick ;

Disparities in immune checkpoint inhibitor utilization and survival based on race and socioeconomic factors in patients with metastatic non-small cell lung cancer (NSCLC) underscore the need for improved access to care for vulnerable...

Disparities in immune checkpoint...

01/15/2025

Journal of Clinical Pathways

Interview

Novel Therapies and Their Impact on Treatment Pathways for Chronic Lymphocytic Leukemia

01/13/2025

Seema A. Bhat , MD;

In this interview, Seema A. Bhat, MD, discusses the evolving treatment landscape for chronic lymphocytic leukemia, including strategies for treatment selection, sequencing, addressing diagnostic gaps, and exploring novel therapies to improve...

In this interview, Seema A....

01/13/2025

Journal of Clinical Pathways

Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplant Program

Current Issue

Special Reports

Subscribe

Recent Stories

Specialties

Events

Year Round Education

HMP Global Products